Clinical Evaluation of Peptides in Gut Health: Larazotide and KPV

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

Clinical Question

Does the current clinical evidence support the use of larazotide-acetate or kpv for stabilizing the intestinal barrier or managing inflammatory bowel conditions?

Evidence Snapshot

Larazotide Acetate

• Evidence Grade: B-
• Study Type: Phase II and Phase III human clinical trials.
• Sample Size: Substantial (specific to Phase II and discontinued Phase III cohorts).
• Primary Outcomes: Modest symptom improvement at low dose (0.5 mg TID); inconsistent results for permeability and histology.

KPV (Lys-Pro-Val)

• Evidence Grade: D+
• Study Type: Preclinical (animal/in vitro) models only.
• Sample Size: N/A (No human subjects).
• Primary Outcomes: Inhibition of NF-kB translocation in IBD models.

What the Research Shows

Larazotide Acetate Larazotide acetate is a locally acting, nonsystemic oral octapeptide. The most robust human evidence for this compound involves its application in celiac disease as an adjunct to a gluten-free diet (GFD). Clinical data indicates a modest symptom improvement signal specifically at a dose of 0.5 mg three times daily (TID). It is categorized as a clinically studied investigational tight-junction regulator.

However, the evidence for objective clinical endpoints remains mixed. While symptom reduction has been noted, trials have shown inconsistent results regarding the normalization of intestinal permeability or improvements in histology. The compound has not been proven to facilitate general gut repair or provide disease modification. Notably, the Phase III CeDLara trial (NCT03569007) was discontinued in June 2022 following an interim analysis which determined there was insufficient separation from the placebo group.

KPV KPV is a C-terminal tripeptide fragment of alpha-melanocyte stimulating hormone (alpha-MSH). Currently, there are zero human clinical trials investigating KPV. Research is restricted to preclinical models of inflammatory bowel disease (IBD). In these models, KPV has demonstrated an ability to inhibit pro-inflammatory pathways. There is currently no human data confirming its efficacy, safety, or biological behavior in clinical settings.

Mechanism

Larazotide Acetate Larazotide acts locally within the gut lumen and does not reach measurable systemic plasma levels. It is designed to stabilize intestinal epithelial tight junctions and preserve paracellular barrier function. Additionally, it has been shown to inhibit the accumulation of macrophages induced by gliadin.

KPV The mechanism of KPV involves the inhibition of NF-kB nuclear translocation. This action leads to a reduction in downstream pro-inflammatory cytokine production. Unlike its parent molecule, alpha-MSH, KPV achieves these effects without triggering melanocortin receptor-mediated side effects.

Limitations of the Evidence

Larazotide Acetate The primary limitation of larazotide research is the inconsistency of objective barrier function data; specifically, the lactulose:mannitol permeability test results have varied across trials. The compound also exhibits a non-monotonic dose response, which complicates the interpretation of its clinical utility. Furthermore, its use for general "leaky gut" is not supported by current evidence. The discontinuation of its Phase III trial highlights significant gaps in proving definitive efficacy for its primary investigated indication.

KPV The evidence for KPV is severely limited by a total lack of human clinical trials. There is no available data regarding human pharmacokinetics (PK) or bioavailability. Furthermore, manufacturing and purity standards for KPV have not been established. It remains in the preclinical stage and lacks regulatory approval for any human use.

Clinical Takeaway

Larazotide acetate has demonstrated modest symptom relief in celiac patients at specific low doses, but it failed to meet Phase III requirements for broader clinical application and is not FDA-approved. KPV remains an experimental tripeptide with no human data to support its clinical use. There is currently no evidence-based support for using these compounds for general intestinal permeability or repair.

Physicians interested in the current landscape of intestinal barrier research may investigate how to find a peptide prescriber who specializes in investigational gastroenterology. Because these compounds are not FDA-approved and their availability varies, clinicians should consult with specialized professionals to understand the regulatory environment. For those looking for resources on how to find a peptide prescriber, established clinical networks can provide guidance on current investigational access.

Sources

• TruthTides Clinical Database: Larazotide Acetate (Record ID: B-)
• TruthTides Clinical Database: KPV (Record ID: D+)
• Clinical Trial Registry: NCT03569007 (CeDLara Phase III)